Scinai Immunotherapeutics (SCNI) Profit After Tax (2014 - 2026)

Scinai Immunotherapeutics has reported Profit After Tax for 13 years, with the latest figure at -$2.5 million in Q1 2026.

• Quarterly Profit After Tax fell 57.33% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.9 million (down 610.3% YoY) and the FY2025 annual result came in at -$11.0 million, down 328.54% from the prior year.
• Profit After Tax eased to -$2.5 million in Q1 2026 per SCNI's latest filing, from -$2.2 million in the prior quarter.
• Over five years, Profit After Tax peaked at $10.5 million in Q3 2024 and troughed at -$10.7 million in Q4 2023.
• A 5-year average of -$1.4 million and a median of -$2.5 million in 2026 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 436.5% in 2024, down 276.5% in 2024.
• Over 5 years, Profit After Tax stood at -$6.5 million in 2022, then tumbled by 64.76% to -$10.7 million in 2023, then soared by 65.92% to -$3.6 million in 2024, then surged by 39.63% to -$2.2 million in 2025, then slipped by 12.39% to -$2.5 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$2.5 million, -$2.2 million, and -$1.6 million for Q1 2026, Q2 2025, and Q1 2025 respectively.